RPID

0.73500.04%
RS

Richard S. Kollender

Independent Director

Mr. Richard S. Kollender, also known as Rich, M.B.A., C.P.A., is Chief Executive Officer of Reaction Biology Corporation from July 2025. Mr. Kollender was CFO & Chief Business Officer of Reaction Biology Corporation from April 04, 2022 to July 2025. He joined Reaction Biology Corporation since April 4, 2022. He serves as Director of Intuilize, Inc. He had been President and Chief Financial Officer at Strongbridge Biopharma plc since March 3, 2021 until March 2022. He serves as Director at Rapid Micro Biosystems, Inc. since October 2018. He served as Chief Operating Officer at Strongbridge Biopharma plc since September 03, 2019 until March 3, 2021. He served as its Director since March 17, 2015 until September 02, 2019. Mr. KolLender has experience in the healthcare industry. He serves as a Director of Tarsa Therapeutics, Inc. He serves on the Board of Directors of PACT (Greater Philadelphia Alliance for Capital and Technologies). He served as the Chief Financial Officer and Chief Business Officer at Rapid Micro Biosystems, Inc. since August 2016 until September 2018 and rejoined as Director, where he played a key role in the business expansion and adoption of the company's Growth Direct (TM) System. He serves as Managing Partner, Partner & Director at Quaker Partners Management, LP since January 2011 and joined the firm in 2003. Mr. KolLender serves as a Partner of Quaker Partners since 2005. He served as Principal at Quaker Partners since joining it in 2003. He has significant biopharmaceutical experience in executive management and venture capital roles. He worked at GlaxoSmithKline plc (GSK), where he held positions in sales, marketing and worldwide business development. During his tenure in business development, he had the opportunity to evaluate both early and late stage compounds for in-licensing, including the successful licensing of Abreva. He served as an Investment Manager of SR One. As a marketer, he served as a Brand Manager in the Oncology and Specialty Products business unit of GSK, where he had both pre-launch and post-launch product management responsibilities. In addition, he was a Founding Member of GSK's eMarketing Group. He also served as an Investment Manager at S.R. One, where he had the opportunity to evaluate potential investment opportunities, perform due diligence, structure and negotiate investments and work with management teams to execute their strategies following investment. He began his career as a Certified Public Accountant with KPMG Peat Marwick and spent six years in public practice. He served as an Accountant of KPMG LLP. His public accounting practice included a significant emphasis on the healthcare and emerging businesses sectors. He served as the Chairman of the Board of Directors at Rapid Micro Biosystems, Inc. He served as a Director at Celator Pharmaceuticals, Inc. since August 2012 and Achillion Pharmaceuticals, Inc. since July 2009. He is also an active Board Observer for Amicus Therapeutics. He served as the Chairman of the Board at TargetRx, Inc. He previously served as a Director of Rapid Micro Biosystems, Inc. since July 2009. He served as a Director NuPathe, Inc. since October 23, 2012 and also from December 2007 to 2011. Mr. KolLender served on the Board of Directors of Strongbridge Biopharma plc, a biopharmaceutical company, from March 2015 to September 2019. He served as a Director of Insmed Incorporated from January 12, 2011 to October 2013. He served on the Boards of Medmark, Transport Pharmaceuticals, Inc. and Corridor Pharmaceuticals, Inc. He served as a Director of Transave LLC and Corcept Therapeutics Incorporated. He served as a Board Observer at Celator Pharmaceuticals, Inc. since 2005. He served as a Director at Precision Therapeutics, Inc. since February 2006. He served as a Director of TargetRx, Inc. since April 2005. He is a member of both the American and Pennsylvania Institutes of Certified Public Accountants. He is also an Adjunct faculty at Lehigh University. He has served as a member of Board since July 2009, except for the period from February 2017 to October 2018 at Rapid Micro Biosystems, Inc. He serves as Chairman of the Board of Directors for Restorative Therapies, Inc. He holds M.B.A. with honors from University of Chicago, Certificate Degree in the Graduate Program in Health Administration and Policy from the University of Chicago and a B.A. in Accounting and Business Administration from Franklin and Marshall College.

Positions